DarioHealth Corp. — Cyborg Score 5/10

Mixed
Digital Health

Strategic Profile

In Q1 2026, DarioHealth achieved its second consecutive quarter of sequential revenue growth alongside continued reductions in operating expenses. The company's channel partner ecosystem now provides access to more than 116 million covered lives through blue-chip partners such as Solera and Amwell, expanding reach into leading national and regional payer organizations across the U.S.

Cyborg Score Rationale

Strong sequential revenue momentum in Q1 2026 with second consecutive quarter of growth and 21% year-over-year operating expense reduction. However, 2025 revenue declined 17.31% to $22.36M from $27.04M in 2024, and losses increased 34% to $40.31M in 2025.

Top Insights

  • DarioHealth customers are realizing up to a 5-fold ROI, with average annual medical cost savings of $5,077 per Dario user.
  • Key competitive advantage is Dario's multi-condition platform covering 6+ conditions, more than any other digital health company on the market today.
  • Company pipeline grew to $127 million as of end of Q1 2026 based on 241+ opportunities.
  • Company is moving closer to care, backed by more than 100 peer-reviewed clinical studies, expanding both its role and revenue model into claims-based and outcomes-driven payments.

Named Competitors

  • Apree Health — Digital health platform for chronic conditions
  • Wildflower Health — Behavioral and digital health solutions
  • MySugr — Diabetes management mobile app
  • Blue Mesa Health — Digital therapeutics platform

Recent Developments

  • (May 2026) Q1 2026 revenue increased to $5.6 million, marking second consecutive quarter of sequential growth with 21% YoY operating expense reduction
  • (April 2026) Published peer-reviewed JMIR Formative Research demonstrating statistically significant improvements in workplace functioning from digital behavioral health program
  • (April 2026) Appointed healthcare executive John R. Palumbo to Board of Directors to support accelerated commercial scaling
  • (March 2026) Q4 2025 results showed full-year revenue of $22.4M with $122M pipeline and $12.9M in contracted/late-stage ARR contracts

Open the full interactive DarioHealth Corp. report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.

Open report →